Clinical trial
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic…
NCT00077363 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077363 |
|---|---|
| Title | Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer |
| Official title | A Phase II Trial of Capecitabine in Combination With the Farnesyltransferase Inhibitor, R115777 (Tipifarnib, Zarnestra) in Patients With Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug |
| Interventions | tipifarnib, capecitabine |
| Enrollment | 70 |
| Start date | May 1, 2004 |
| Primary completion | Feb 1, 2007 |
| First posted | Feb 12, 2004 |
| Last update posted | Feb 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: